Clinical Evidence
The Evidence for
ChondroFiller® Regeneration
ChondroFiller® has a published evidence base across knee, hip, ankle and small-joint applications. Below: what the evidence shows, what the headline outcome numbers mean, and what the evidence cannot tell you.
Reviewed byProf Paul Lee MBBch, FRCS (Tr & Orth), PhDLast reviewed 1 May 2026Quick Answer
Published clinical evidence supports ChondroFiller® for focal cartilage defects in the knee, hip, ankle and small joints. Headline outcomes include +30 IKDC scores in knees, +33 Harris Hip Score in hips, and MOCART MRI regeneration scores of 70 to 87. Over 19,000 ChondroFiller® cases have been performed globally. Outcomes vary by defect size, location, surrounding cartilage quality and patient suitability; the evidence base continues to grow.
Watch: The Mechanism
ChondroFiller® scaffold and cell migration, on video
A short manufacturer video showing how the ChondroFiller® collagen scaffold is placed into a cartilage defect and how the body’s own cells migrate in to rebuild tissue. The figures below sit on top of this biology.
ChondroFiller® is a registered trademark of Meidrix Biomedicals GmbH.
Headline Outcomes
What the published evidence shows
The numbers below come from published peer-reviewed clinical studies on ChondroFiller® across multiple international centres. Individual outcomes vary.
Evidence Coverage
What the evidence covers
ChondroFiller® has been studied across multiple joints and clinical contexts. The evidence base is most mature in the knee but extends meaningfully across the hip, ankle and smaller joints.
Knee — focal cartilage defects
Published outcomes in chondral and osteochondral defects of the knee, including post-traumatic lesions and osteochondritis dissecans (OCD). IKDC improvements of +30 points are typical in suitable patients.
Hip — focal cartilage defects and FAI
Published evidence in focal hip cartilage damage and femoroacetabular impingement (FAI). Harris Hip Score improvements of +33 points have been reported in studied patients.
Ankle — chondral and osteochondral lesions
Evidence supports ChondroFiller® use in ankle cartilage lesions, including focal chondral damage from sports injuries and osteochondral lesions of the talus.
Small joints — hand, wrist, thumb
Published case-series in thumb carpometacarpal (CMC) arthritis and wrist cartilage reconstruction including distal radius fractures with intra-articular involvement.
Cell-free, scaffold-based mechanism
Multiple papers describe the cell-free scaffold mechanism. No cells are harvested, cultured or implanted; the body’s own resident cells migrate into the scaffold and lay down hyaline-like tissue.
Safety profile across joint applications
Safety data from over 19,000 global cases supports a low rate of complications across joint applications. As with any joint injection, sterile technique and clinical follow-up are essential.
What This Means For You
What the evidence means if you are considering ChondroFiller®
The published evidence supports ChondroFiller® for selected focal cartilage defects. It does not mean every patient with cartilage damage is a candidate, and it does not promise the same headline outcome for every individual.
Suitability matters more than the average. The IKDC, Harris Hip Score and MOCART improvements above come from patients selected to be likely responders, with appropriate defect size, location and joint mechanics. A patient with widespread bone-on-bone arthritis, untreated instability or a defect significantly larger than 6 cm² is unlikely to match those outcomes. See the ChondroFiller® suitability page for the patient-selection framework.
Regeneration takes time. Unlike a cushioning hydrogel that can offer symptom relief in days to weeks, a regenerative scaffold takes six to twelve months for new tissue to establish meaningfully. Most patients begin to notice improvement at six to twelve weeks, with continued benefit building.
Real-world LCC data is in preparation. London Cartilage Clinic maintains an outcome database of all our ChondroFiller® patients. The clinic-specific real-world series is being prepared for publication and will sit alongside the existing international evidence on this page when ready.
Evidence is not a guarantee. A regenerative product cannot guarantee regeneration for any specific patient. Imaging review and clinical assessment at consultation are what tell us how close your case sits to the studied patient profile.
Peer-Reviewed Research
Published papers on ChondroFiller®
Twelve peer-reviewed papers covering animal models, cell-free mechanism, knee, hip, ankle, hand, wrist, and safety across applications. Download any of the papers below.
Animal Study
Preclinical evaluation of ChondroFiller® in animal models.
Download PDFArthritis of the Thumb
Application of ChondroFiller® in thumb carpometacarpal arthritis.
Download PDFBehaviour of Human Cartilage
Insights into cartilage response and regeneration potential.
Download PDFCartilage Reconstruction in Distal Radius Fractures
Case-based reconstruction of wrist joint cartilage defects.
Download PDFCell-Free Approach
Concept and outcomes of scaffold-based, cell-free cartilage repair.
Download PDFCollagen Matrix for Cartilage Repair
Structural collagen scaffolds and their role in joint preservation.
Download PDFFemoroacetabular Impingement
Managing hip impingement with structural cartilage regeneration.
Download PDFHip Defects
Treatment of focal cartilage lesions in the hip joint.
Download PDFNeedle and Curette Technique
Minimal access technique for preparing cartilage defects.
Download PDFOsteoid Osteoma
Managing osteoid osteoma with joint surface restoration.
Download PDFRegeneration of Cartilage Defects
Outcomes of defect-filling regenerative strategies.
Download PDFSafety of ChondroFiller®
Safety data and complication profile from clinical use.
Download PDF
Honest Caveats
Limitations of the evidence
Evidence base is still maturing in the UK
ChondroFiller® has been available for over a decade in Europe, with a growing body of peer-reviewed work. As an injection in the UK it is comparatively new (London Cartilage Clinic was the first to offer it this way). Our own real-world series is in preparation for publication.
Outcomes vary by defect size and joint
The headline IKDC, Harris Hip Score and MOCART numbers come from selected patients with appropriate defects. Defects significantly larger than 6 cm², or in joints with extensive degeneration, do not match the studied profile.
Long-term durability is still being studied
Regenerated cartilage is biological tissue; once it is laid down, it persists. But long-term follow-up beyond five to ten years is still being collected across international centres. We tell patients honestly what the evidence does and does not yet show.
Not a substitute for joint replacement
ChondroFiller® is for focal defects in an otherwise preserved joint. Where the joint surface has been substantially lost across a wide area, joint replacement may still be the right answer. The evidence supports preservation in selected cases, not universal avoidance of surgery.
Individual variability is intrinsic
Regeneration depends on the body’s own cells migrating into the scaffold and laying down hyaline-like tissue. Patient biology, comorbidities, activity demands and rehabilitation all influence the outcome. No regenerative product can guarantee a specific result.
Evidence Into Decision
How close is your case to the studied patient profile?
Suitability for ChondroFiller® depends on defect size, location, surrounding cartilage and joint mechanics. The published evidence applies most strongly to selected focal defects, not to every cartilage problem. Start with imaging review and a free discovery call.
ChondroFiller® Evidence
Frequently asked questions
Does ChondroFiller® really regenerate cartilage?
Yes, in suitable patients. ChondroFiller® is an acellular collagen scaffold; the body’s own cells migrate into the scaffold and build hyaline-like cartilage in the defect over the following months. Published outcome data shows +30 IKDC scores in knees, +33 Harris Hip Score in hips, and MOCART MRI regeneration scores of 70 to 87. Outcomes depend on defect size, location, surrounding cartilage quality and patient biology.
How long do ChondroFiller® results take to appear?
ChondroFiller® is a regenerative scaffold, not an immediate pain-relief injection. Most patients begin to notice improvement at six to twelve weeks, with continued benefit building over six to twelve months as new tissue establishes within the scaffold. Published MOCART MRI scores improve over the same period, reflecting cartilage that is laying down rather than disappearing.
How long do ChondroFiller® results last?
Once the scaffold has been populated by the body’s own cells and new cartilage has laid down, the regenerated tissue is biological and persists. ChondroFiller® aims to preserve the joint rather than mask symptoms, so the duration question is less about “how long does the product last” and more about “how durable is the cartilage that grows.” Outcomes vary; we follow up at six weeks and discuss longer term follow-up at consultation.
Who responds best to ChondroFiller®?
Patients with a focal cartilage defect on imaging (typically up to around 6 cm²), stable joint mechanics, realistic expectations and a goal of joint preservation tend to respond best. Patients with widespread bone-on-bone arthritis or untreated mechanical instability are less suitable. See the ChondroFiller® suitability page for the full picture.
What happens if ChondroFiller® does not work for me?
A minority of patients do not get the expected level of regeneration. If MRI at six to twelve months does not show meaningful cartilage establishment, or symptoms persist, we re-review imaging and clinical findings. Options may include a further treatment, the Liquid Cartilage™ keyhole-surgery pathway (our proprietary technique combining ChondroFiller® with MSC co-delivery in a single arthroscopic procedure), or an alternative cartilage repair procedure. We will be honest if a different pathway is the better answer.
Is the ChondroFiller® evidence peer-reviewed?
Yes. ChondroFiller® has a peer-reviewed evidence base across multiple international centres, covering knee, hip, ankle and small-joint applications. The published papers are listed on the ChondroFiller® hub page. Our own real-world outcome data from LCC patients is in preparation for publication.
Will ChondroFiller® prevent me from needing a knee replacement?
ChondroFiller® is not a substitute for knee replacement where replacement is clinically appropriate. In selected patients with focal cartilage damage in an otherwise preserved joint, ChondroFiller® may help avoid or delay knee replacement by addressing the defect before it progresses to widespread arthritis. In end-stage bone-on-bone disease, the regenerative scaffold has little to anchor into.
Book a ChondroFiller® Assessment – London
Natural cartilage regeneration starts with the right defect, the right operator, and the right plan.
Learn More about ChondroFiller
Deep dive into our clinical resources and patient guides.
Cost in the UK
ChondroFiller® cost in the UK from £3,000, what is included and why prices vary.
Suitability
Who is suitable for ChondroFiller® as an injection, and who may need caution.
Clinical Evidence
IKDC, Harris Hip Score and MOCART MRI outcomes for ChondroFiller® cartilage regeneration.
Self-Assessment
Five-question ChondroFiller® pathway self-assessment for Prevention, Regeneration, Combination, or Support.
In London
Private ChondroFiller® cartilage repair at our Harley Street clinic.
Liquid Cartilage™ Surgery
Our proprietary keyhole-surgery technique combining ChondroFiller® with MSC co-delivery in a single procedure, for larger or more complex cartilage defects. £9,800.
ChondroFiller vs Arthrosamid
Cartilage regeneration vs joint cushioning, two very different injections.
ChondroFiller vs Hyaluronic Acid
Structural scaffold for cartilage regeneration vs joint-lubricant viscosupplement.
ChondroFiller vs Microfracture
ChondroFiller® regeneration compared to microfracture surgery for cartilage defects.
ChondroFiller vs MACI
ChondroFiller® scaffold compared to matrix-induced autologous chondrocyte implantation.
ChondroFiller vs ACI
ChondroFiller® scaffold compared to the original autologous chondrocyte implantation technique.
ChondroFiller vs PRP
ChondroFiller® cartilage regeneration compared to platelet-rich plasma injection.
ChondroFiller vs Stem Cells
ChondroFiller® compared to stem cell and biologic regenerative treatments.
ChondroFiller vs Knee Replacement
Where ChondroFiller® may help preserve the joint and where replacement is the right answer.
ChondroFiller® Injection
Cartilage Regeneration Overview
ChondroFiller® is a registered trademark of Meidrix Biomedicals GmbH. London Cartilage Clinic is not affiliated with or endorsed by Meidrix Biomedicals.